The Medicines and Healthcare Products Regulatory Agency (MHRA) has awarded the first 'innovation passport' under a new scheme to reduce the time for innovative medicines to get to market, known as the Innovative Licensing and Access Pathway (ILAP).
We look forward to seeing medicines coming through this scheme and getting to the people who need them as quickly as possible. Richard Torbett, Chief Executive, ABPI
In response, ABPI Chief Executive Richard Torbett said:
“It’s great to see the ILAP moving forward quickly with the award of the first innovation passport.
“Now the MHRA is a sovereign medicines regulator, this scheme is a really positive sign that the UK is serious about accelerating the approval of innovative new medicines, which is a win for patients, the NHS and industry.
“We look forward to seeing medicines coming through this scheme and getting to the people who need them as quickly as possible.”
Last modified: 20 September 2023
Last reviewed: 20 September 2023